Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Terminated 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Recurrence 6Hodgkin Disease 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Leukemia 3Hematologic Neoplasms 3Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Anemia, Refractory, with Excess of Blasts 2Transplant-Related Hematologic Malignancy 1Teratoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

Cyclophosphamide 8fludarabine 6cabozantinib 5Temozolomide 4Doxorubicin 4Zoledronic Acid 3X-Rays 3Vincristine 3Methotrexate 3Ifosfamide 3Gemcitabine 3Cisplatin 3irinotecan sucrosofate 2atezolizumab 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiosurgery 2Phantoms, Imaging 2Mesna 2Magnetic Resonance Spectroscopy 2Irinotecan 2Eflornithine 2Disulfiram 2Biopsy 2vactosertib 1trilaciclib 1trametinib 1talazoparib 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Osteosarcoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡